1
|
Malara A, Gruppi C, Abbonante V, Cattaneo D, De Marco L, Massa M, Iurlo A, Gianelli U, Balduini CL, Tira ME, Muro AF, Chauhan AK, Rosti V, Barosi G, Balduini A. EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. J Exp Med 2019; 216:587-604. [PMID: 30733282 PMCID: PMC6400533 DOI: 10.1084/jem.20181074] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 11/26/2018] [Accepted: 01/09/2019] [Indexed: 12/24/2022] Open
Abstract
The fibronectin EDA isoform sustains bone marrow fibrosis, binding to TLR4 on megakaryocytes and inducing NF-κB activation and IL-6 release. In primary myelofibrosis patients, the bone marrow fibrosis correlates with increased levels of fibronectin EDA isoform in plasma. The fibronectin EDA isoform (EDA FN) is instrumental in fibrogenesis but, to date, its expression and function in bone marrow (BM) fibrosis have not been explored. We found that mice constitutively expressing the EDA domain (EIIIA+/+), but not EDA knockout mice, are more prone to develop BM fibrosis upon treatment with the thrombopoietin (TPO) mimetic romiplostim (TPOhigh). Mechanistically, EDA FN binds to TLR4 and sustains progenitor cell proliferation and megakaryopoiesis in a TPO-independent fashion, inducing LPS-like responses, such as NF-κB activation and release of profibrotic IL-6. Pharmacological inhibition of TLR4 or TLR4 deletion in TPOhigh mice abrogated Mk hyperplasia, BM fibrosis, IL-6 release, extramedullary hematopoiesis, and splenomegaly. Finally, developing a novel ELISA assay, we analyzed samples from patients affected by primary myelofibrosis (PMF), a well-known pathological situation caused by altered TPO signaling, and found that the EDA FN is increased in plasma and BM biopsies of PMF patients as compared with healthy controls, correlating with fibrotic phase.
Collapse
Affiliation(s)
- Alessandro Malara
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.,Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, Istituto di Ricovero e Cura a Carattere Scientific San Matteo Foundation, Pavia, Italy
| | - Cristian Gruppi
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - Vittorio Abbonante
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.,Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, Istituto di Ricovero e Cura a Carattere Scientific San Matteo Foundation, Pavia, Italy
| | - Daniele Cattaneo
- Hematology Division, Istituto di Ricovero e Cura a Carattere Scientific Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy
| | - Luigi De Marco
- Department of Translational Research, National Cancer Center (Istituto di Ricovero e Cura a Carattere Scientific Centro di Riferimento Oncologico), Aviano, Italy.,Department of Molecular and Experimental Research, The Scripps Research Institute, La Jolla, CA
| | - Margherita Massa
- Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, Istituto di Ricovero e Cura a Carattere Scientific San Matteo Foundation, Pavia, Italy
| | - Alessandra Iurlo
- Hematology Division, Istituto di Ricovero e Cura a Carattere Scientific Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy
| | - Umberto Gianelli
- Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - Carlo L Balduini
- Department of Internal Medicine, Istituto di Ricovero e Cura a Carattere Scientific San Matteo Foundation, Pavia, Italy
| | - Maria E Tira
- Department of Biology and Biotechnology "Lazzaro Spallanzani," University of Pavia, Pavia, Italy
| | - Andrès F Muro
- The International Center for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Anil K Chauhan
- Department of Internal Medicine, University of Iowa, Iowa City, IA
| | - Vittorio Rosti
- Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, Istituto di Ricovero e Cura a Carattere Scientific Policlinico S. Matteo Foundation, Pavia, Italy
| | - Giovanni Barosi
- Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, Istituto di Ricovero e Cura a Carattere Scientific Policlinico S. Matteo Foundation, Pavia, Italy
| | - Alessandra Balduini
- Department of Molecular Medicine, University of Pavia, Pavia, Italy .,Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, Istituto di Ricovero e Cura a Carattere Scientific San Matteo Foundation, Pavia, Italy.,Department of Biomedical Engineering, Tufts University, Medford, MA
| |
Collapse
|
2
|
Curci G, Frassoldati A, Zioni F, Zaniol P, Piccinini L. Plasma Fibronectin in Hemoblastosis. Int J Biol Markers 1987; 2:71-4. [PMID: 3451931 DOI: 10.1177/172460088700200203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Fibronection (FN) is a glycoprotein whose plasma concentrations are reduced in many pathological conditions. In patients with hemoblastosis plasma FN was correlated with some clinical and biological parameters (stage of the disease, hepatosplenomegaly, infections and DIC), in order to assess its value as a tumor marker. The results suggest a poor relationship between FN levels and the course of the disease. However, the behaviour of the protein in relation with treatment was dynamic.
Collapse
Affiliation(s)
- G Curci
- Cattedra di Terapia Medica Sistematica, University of Modena, Italy
| | | | | | | | | |
Collapse
|